130 related articles for article (PubMed ID: 34848450)
1. GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
Motomura H; Tamori S; Yatani MA; Namiki A; Onaga C; Ozaki A; Takasawa R; Mano Y; Sato T; Hara Y; Sato K; Xiong Y; Harada Y; Hanawa T; Tanuma SI; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2021 Dec; 41(12):5959-5971. PubMed ID: 34848450
[TBL] [Abstract][Full Text] [Related]
2. High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
Nozaki Y; Motomura H; Tamori S; Kimura Y; Onaga C; Kanai S; Ishihara Y; Ozaki A; Hara Y; Harada Y; Mano Y; Sato T; Sato K; Sasaki K; Ishiguro H; Ohno S; Akimoto K
PLoS One; 2020; 15(7):e0235747. PubMed ID: 32658903
[TBL] [Abstract][Full Text] [Related]
3. High Expression of
Motomura H; Nozaki Y; Onaga C; Ozaki A; Tamori S; Shiina TA; Kanai S; Ohira C; Hara Y; Harada Y; Takasawa R; Hanawa T; Tanuma SI; Mano Y; Sato T; Sato K; Akimoto K
Anticancer Res; 2020 Jan; 40(1):35-52. PubMed ID: 31892551
[TBL] [Abstract][Full Text] [Related]
4. High expression of PKCλ and ALDH1A3 indicates a poor prognosis, and PKCλ is required for the asymmetric cell division of ALDH1A3-positive cancer stem cells in PDAC.
Kasai T; Tamori S; Takasaki Y; Matsuoka I; Ozaki A; Matsuda C; Harada Y; Sasaki K; Ohno S; Akimoto K
Biochem Biophys Res Commun; 2023 Aug; 669():85-94. PubMed ID: 37267864
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
6. Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer.
Motomura H; Ozaki A; Tamori S; Onaga C; Nozaki Y; Waki Y; Takasawa R; Yoshizawa K; Mano Y; Sato T; Sasaki K; Ishiguro H; Miyagi Y; Nagashima Y; Yamamoto K; Sato K; Hanawa T; Tanuma SI; Ohno S; Akimoto K
Oncol Lett; 2021 Jul; 22(1):547. PubMed ID: 34093768
[TBL] [Abstract][Full Text] [Related]
7. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.
Schwartz T; Stark A; Pang J; Awuah B; Kleer CG; Quayson S; Kingman S; Aitpillah F; Abantanga F; Jiagge E; Oppong JK; Osei-Bonsu E; Martin I; Yan X; Toy K; Adjei E; Wicha M; Newman LA
Cancer; 2013 Feb; 119(3):488-94. PubMed ID: 22930220
[TBL] [Abstract][Full Text] [Related]
8. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
10. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
[TBL] [Abstract][Full Text] [Related]
11. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
12. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
14. ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer.
Panigoro SS; Kurnia D; Kurnia A; Haryono SJ; Albar ZA
Int J Surg Oncol; 2020; 2020():7863243. PubMed ID: 32695508
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
Ma F; Li H; Li Y; Ding X; Wang H; Fan Y; Lin C; Qian H; Xu B
Medicine (Baltimore); 2017 Apr; 96(14):e6561. PubMed ID: 28383433
[TBL] [Abstract][Full Text] [Related]
16. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells.
Tsukabe M; Shimazu K; Morimoto K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Kim SJ; Noguchi S
Oncology; 2013; 85(4):248-56. PubMed ID: 24192633
[TBL] [Abstract][Full Text] [Related]
18. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
19. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
20. High Expression of
Ozaki A; Motomura H; Tamori S; Onaga C; Nagashima Y; Kotori M; Matsuda C; Matsuda A; Mochizuki N; Sato T; Hara Y; Sato K; Miyagi Y; Nagashima Y; Hanawa T; Harada Y; Xiong Y; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2022 Jul; 42(7):3299-3312. PubMed ID: 35790283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
